Cranial radiation and concomitant cisplatin and mitomycin-C plus resistance modulators for malignant gliomas

Journal of Neuro-Oncology

Volumn 32, Issue 2, 1997, Pages 161-168

  Stewart, David J ^a,b   Dahrouge, Simone ^a,b   Agboola, Olu ^a,b   Girard, André ^a,b  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Beta carotene; Chemotherapy; Cisplatin; Dipyridamole; Metronidazole; Mitomycin C; Pentoxifylline; Resistance modulators

Indexed keywords

BETA CAROTENE; CISPLATIN; DIPYRIDAMOLE; METRONIDAZOLE; MITOMYCIN C; PENTOXIFYLLINE;

ADULT; AGED; ANOREXIA; ARTICLE; ASTROCYTOMA; BRAIN RADIATION; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DROWSINESS; DRUG EFFICACY; FEMALE; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUCOSA INFLAMMATION; MUSCLE WEAKNESS; NAUSEA; NEUROTOXICITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; OTOTOXICITY; RADIATION DOSE; RECTAL DRUG ADMINISTRATION; SEIZURE; SKIN TOXICITY; UNCONSCIOUSNESS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA CAROTENE; BRAIN NEOPLASMS; CISPLATIN; COMBINED MODALITY THERAPY; DIPYRIDAMOLE; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; GLIOBLASTOMA; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; MITOMYCIN; PENTOXIFYLLINE; TREATMENT OUTCOME;

EID: 0031040639     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005788121043     Document Type: Article

References (45)

1. Stewart DJ: The role of chemotherapy in the treatment of gliomas in adults. Can Treat Rev 16: 129-160, 1989
2. Fine HA, Dear KBG, Loeffler JS, Black PM, Canellos GP: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71 (8): 2585-2597, 1993
3. Teicher BA, Holden SA, Al-Achi A, Herman TS: Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSa II C murine fibrosarcoma. Cancer Res 50: 3339-3344, 1990
4. Fu KK, Rayner PA, Lam KN: Modification of the effects of continuous chemotherapy infusion. Int J Rad Oncol Biol Phys 10: 1473-1478, 1984
5. Rauth AM, Mohindra JK, Rannock IF: Activity of mitomycin-C for aerobic and hypoxic cells in vitro and in vivo. Cancer Res 43: 4154-4158, 1983
6. Scholds C: Personal communication, 1994
7. Douple EB, Richmond RC: Platinum complexes as radiosensitizers of hypoxic mammalian cells. Br J Cancer 37: 98-102, 1978
8. Decker DA, Kinzie J, Evans R, Abu-zahra H, Al-Sarraf M: Pilot study of combination 5-fluorouracil, cisdiamminedichloroplatinum II, and radiation therapy for grade III and IV astrocytomas. Am J Clin Oncol (CCT) 10 (5): 444-447, 1987
9. Feun LG, Stewart DJ, Maor M, Leavens M, Savaraj N, Burgess MA, Yung WKA, Benjamin RS: A pilot study of cisdiamminedichloroplatinum and radiotherapy in patients with high grade astrocytomas. J Neuro-Oncol 1: 109-113, 1983
10. Durand RD: Synergism of cisplatin and mitomycin-C in sensitive and resistant cell subpopulations of a tumor model. Int J Cancer 44: 911-917, 1989
11. Zijlstra JG, DeVries EGE, Mulder NH: Multifactorial drug resistance in adriamycin-resistant human small cell lung carcinoma cell line. Can Res 47: 1780-1784, 1987
12. Mansouri A, Kurt JH, Nagle WA: Tumor drug-resistance: A challenge to therapist and biologists. Am J Med Sci 307: 438-444, 1994
13. Stewart DJ, Evans WK: Non-chemotherapeutic agents potentiate chemotherapy efficacy. Cancer Treat Rev 16: 1-40, 1989
14. Clement JJ, Johnson RK: Evaluation of radiosensitizers in combination with chemotherapeutic agents in solid tumors. Int J Rad Oncol Biol Phys 8: 631-634, 1982
15. Roizin-Towle LA, Hall EJ: Enhanced cytotoxicity of anti-neoplastic agents following prolonged exposure to misonidazole. Br J Cancer 44: 202-207, 1981
16. Siemann DW, Hill SA: Enhanced tumor responses through therapies combining CCNU, miso and radiation. Int J Radiat Oncol Biol Phys 10: 1623-1626, 1984
17. Siemann DW, Maddison K, Wolf K, Hill SA, Keng PC: In vivo interaction between radiation and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in the absence or presence of misonidazole in mice. Cancer Res 45: 198-202, 1985
18. Teicher BA, Holden SA, Herman TS, Epelbaum R, Pardee AB, Dezube B: Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo. Anticancer Res 11: 1555-1560, 1991
19. Boike GM, Petru E, Sevin B-U, Averette HE, Chou R-C, Penalver M, Donato D, Schiano M, Hilsenbeck SG, Perras J: Chemical enhancement of cisplatin cytotoxicity in a human ovarian and cervical cancer cell line. Gyn Oncol 38: 315-322, 1990
20. Boike G, Young J, Sightler S, Averette H: Phase I pharmacokinetic study of escalating pentoxifylline with cisplatin in recurrent gynecologic (gyn) cancers. Proc AACR 33: A1330, 1992
21. Kyriazis A P, Kyriazis A A, Yagoda A : Enhanced therapeutic effect of cis-diamminedichloroplatinum II against nude mouse grown human pancreatic adenocarcinoma when combined with 1-a-D-Arabinofuranosylcytosine and caffeine. Cancer Res 45: 6083-6087, 1985
22. Fingert HJ, Alley MC, Lieber MM, Pardee AB: Enhanced lethality by methylxanthines in human bladder cancer cells treated with thiotepa or mitomycin-C. Proc AACR 25: 354, 1984
23. Aviado DM, Dettelback HR: Pharmacology of pentoxifylline a hemorheologic agent for the treatment of intermittent claudication. Angiology 35: 407-417, 1984
24. Nakagawa M, Yamaguchi T, Ueda H, Shirishi N, Komiyama S, Akiyama S, Ogata J, Kuwano M: Potentiation by vitamin A of the action of anticancer agents against murine tumors. Jpn J Cancer Res (Gann) 76: 887-894, 1985
25. Rutka JT, De Armond SJ, Giblin J, McCulloch JR, Wilson CB, Rosenblum ML: Effects of retinoids on the proliferations, morphology and expression of glial fibrillary acidic protein of an anaplastic astrocytoma cell line. Int J Cancer 42: 419-427, 1988
26. Boone CW, Kelloff GJ, Malone WE: Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: a review. Cancer Res 50: 2-9, 1990
27. Howell SB, Vick J, Andrews PA. Biochemical modulation of cisplatin by dipyridamole. Proc AACR 28: 313, 1987
28. Stewart DJ, Goel R, Verma S, Perrault D, Cripps C: Carboplatin plus multiple resistance modulators. Proc AACR: A1405, 1992
29. Stewart DJ, Goel R, Huan SD, Cripps MC, Yau JC, Soltys K, Prosser A, Bourcier J, Paul M, Evans WK, Gallant G: Etoposide plus multiple resistance modulators. Proc ASCO 12: A407, 1993
30. Stewart DJ, Goel R, Dahrouge S, Yau J, Tomiak E, Huan S, Cripps MC: Epirubicin plus multiple chemotherapy resistance modulators in the treatment of resistant malignancies. Cancer Chemather Pharmacol. In Press
31. Chang CH, Horton J, Schoenfeld D, Salazer O, Perez-Tamayo R, Kramer S, Weinstein A, Nelson JS, Tsukada Y: Comparison of postoperative radiotherapy and combined postoperative radiotherapy in the multidisciplinary management of malignant gliomas. Cancer 52: 997-1007, 1983
32. EORTC Brain Tumor Group: Cisplatin does not enhance the effect of radiation therapy in malignant gliomas. Eur J Cancer 27 (5): 571-575, 1991
33. Grem JL, Fischer PH: Alteration of fluorouracil metabolism in human colon cancer cells by dipyridamole with a selective increase in fluorodeoxyuridine monophosphate levels. Cancer Res 46: 6191-6199, 1986
34. Carlson RW, Coleman CN, Kohler M, Gribble MH, Halsey J: A randomized phase II study of L-PAM versus L-PAM + the chemosensitizer misonidazole (MISO) for non-small cell lung cancer (NSCLC): a Northern California Oncology Groups study. Proc ASCO 6: 28, 1987
35. Webster LT Jr: Drugs used in the chemotherapy of protozoal infections. In: Gilman AG, Rall TW, Nies AS, Taylor P (eds) Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed., Pergamon Press, New York, NY 999-1007, 1990
36. Stewart DJ, Leavens M, Maor M, Feun L, Luna M, Bonura J, Caprioli R, Loo TL, Benjamin RS: Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Res 42: 2474-2479, 1982
37. Stewart DJ, Richard M, Hugenholtz HN, Benoit B, Russell N, Dennery J, Peterson E, Maroun JA: Cisplatin plus cytosine arabinoside in adults with malignant gliomas. J NeuroOncol 2: 29-34, 1984
38. Stewart DJ, Benoit B, Hugenholtz H, Maroun JA, Russell N, Richard MT, Peterson E, Dennery J, Nabwangu JF, Grahovac Z, Belanger G, Assang W, Hopkins HS, Girard A: Cisplatin, arabinofuranosyl cytosine, and caffeine before radiation for glioblastomas. In: Walker MD, Thomas DGT (eds) Biology of Brain Tumor, Martinus Nijhoff Publishers, Boston 393-398, 1986
39. Rutka JT, De Armond SJ, Giblin J, McCulloch JR, Wilson CB, Rosenblum ML: Effect of retinoids on the proliferation, morphology and expression of glial fibrillary acidic protein of an anaplastic astrocytoma cell line. Int J Cancer 42: 419-427, 1988
40. Ali-Osman F, Berger MS, Rajagopal S, Spence A, Livingston RB: Topoisomerase II inhibition and altered kinetics of formation and repair of nitrosourea and cisplatin-induced DNA interstrand cross-links and cytotoxicity in human glioblastoma cells. Cancer Res 53: 5663-5668, 1993
41. Robert J, Huet S, Bennis S, Chapey C: Comparison of twelve MDR modulating agents in a model of doxorubicin-resistant rat glioblastoma cells in vitro. 4th Internation Congress of Anti-Cancer Chemotherapy, February 2-5, 1993, Paris, France
42. Urtasun RC, Band P, Chapman JD, Feldstein ML, Mielke B, Fryer C: Radiation and high dose metronidazole in supratentorial glioblastomas. N Eng J Med 294: 1364-1367, 1976
43. Dische S: Chemical sensitizers for hypoxic cells: A decade of experience in clinical radiotherapy. Radiother Oncol 3: 97-115, 1985
44. Stewart DJ, Benoit B, Richard MT, Hugenholtz H, Dennery J, Russell N, Peterson E, Grahovac Z, Belanger G, Maroun JA, Young V: Treatment of malignant gliomas in adults with BCNU plus metronidazole. J Neuro-Oncol 2: 53-58, 1984
45. Stewart DJ, Raaphorst P, Yau J, Beaubien A: Active vs passive resistance, dose-response relationships, high dose chemotherapy, and resistance modulation: a hypothesis. Invest New Drugs 14: 115-130, 1996